What type of study is this?

September 10, 2025Archive of oncologyOpen Access

The efficacy of durvalumab in locally advanced lung carcinoma

View Full Paper

Ask AI

Bookmark

Durvalumab achieved a partial response in 36% of patients, indicating its efficacy as consolidation therapy after chemoradiotherapy.
Overall response rate was recorded at 36% with a mean progression-free survival of 19.8 months observed across the cohort.
Retrospective analysis among 25 stage III NSCLC patients focused on demographic factors and treatment outcomes using iRECIST criteria.
Findings suggest adenocarcinoma subtype, female gender, and PDL-1 expression may correlate with more favorable outcomes, warranting further investigation.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis reports a 36% overall response rate in stage III NSCLC patients, highlighting durvalumab's clinical benefit.

Kneževic et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark